William V. Bobo | Psychiatrist.com

Letter to the Editor

BMI and Remission in Depressed Patients Receiving IV Ketamine

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...

Original Research

Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

Original Research

A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

Original Research

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...

Book Review

The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis

Letter to the Editor

Potential Association Between Risperidone and Cerebrovascular Events

Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

Original Research

Urine Drug Screens and Youth Mortality

Current practices for estimating the risk for mortality in teenage substance users rely heavily on clinical intuition. This study examined whether a positive urine drug screen in youth receiving...